alertmeipp
5 minutes ago
Agree, without virology related costs, they become a preclinical with tons of cash and 60mm annual royalty income - ideally they slash the cost to match royalties plus interest income. No reason they can’t.
If that happened, I think market would react positively. If not, they should r